Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis?

12 Feb 2009

Abstract excerpt

Pulmonary fibrosis represents a fatal stage of interstitial lung diseases of known and idiopathic aetiology. No effective therapy is currently available. Based on an indication-discovery approach we present novel in vitro evidence that the histone deacetylases inhibitor suberoylanilide hydroxamic acid (SAHA), an FDA approved anti-cancer drug, has antifibrotic and anti-inflammatory potential. Human lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Macrophage Migration Inhibitory Factor
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19224893
DOI: 10.1183/09031936.00084808

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis?PMID 19224893Read ↗

Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosisSemantic proximity Read ↗

Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer DisordersSemantic proximity Read ↗

Histone Deacetylase Inhibitors: Development of Suberoylanilide Hydroxamic Acid (SAHA) for the Treatment of CancersSemantic proximity Read ↗

<i>In vitro</i> and <i>ex vivo</i> evaluation of second‐generation histone deacetylase inhibitors for the treatment of spinal muscular atrophySemantic proximity Read ↗

Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic OptionSemantic proximity Read ↗

Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosisSemantic proximity Read ↗

TGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repressionSemantic proximity Read ↗

Restoration of Foxp3+ Regulatory T Cells by HDAC-Dependent Epigenetic Modulation Plays a Pivotal Role in Resolving Pulmonary Arterial Hypertension PathologySemantic proximity Read ↗

Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?Semantic proximity Read ↗

Differential Transcriptomic Modulation by Histone Deacetylase Inhibitor SAHA in LUAD and LUSCSemantic proximity Read ↗

Prevention of Drug-Induced Lung Fibrosis via Inhibition of the MRTF/SRF Transcription PathwaySemantic proximity Read ↗

Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory DiseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.